Prana Biotechnology Ltd. (NASDAQ: PRAN) has developed a proprietary portfolio of class-leading chemical compounds. The company combines this portfolio of compounds with a drug development program to discover novel therapeutics in multiple disease indications. Prana’s focus is currently on meeting the needs of patients diagnosed with neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases. For further information, visit the Company’s web site at www.pranabio.com.
- 18 years ago
QualityStocks
Prana Biotechnology Ltd. (NASDAQ: PRAN)
Tags Rodman & Renshaw
Related Post
-
Mobilicom Ltd. (NASDAQ: MOB) Builds on $2.2 Million in Orders with Pipeline of Nine Tier-1 Design Wins Globally
Late last year, the Pentagon launched a $1 billion drone dominance program, with U.S. Secretary…
-
Gold Prices Rebound with Democratic Midterm Sweep In US
Disseminated on behalf of LaFleur Minerals Inc. and may include paid advertising. LaFleur Minerals Inc.…
-
Barry Ritholtz Joins Howard Lindzon to Open the Stocktoberfest 2026 Programming Day
The programming day of Stocktoberfest presented by Tradr ETFs opened on October 7 at City…